| Literature DB >> 29212628 |
Amanda Pereira-Salgado1,2, Jennifer A Westwood3, Lahiru Russell4, Anna Ugalde4, Bronwen Ortlepp5, John F Seymour6,7, Phyllis Butow8, Lawrence Cavedon9, Kevin Ong9, Sanchia Aranda3,10, Sibilah Breen3,11, Suzanne Kirsa12,13, Andrew Dunlevie3, Penelope Schofield3,7,14.
Abstract
BACKGROUND: Optimal dosing of oral tyrosine kinase inhibitor therapy is critical to treatment success and survival of patients with chronic myeloid leukemia (CML). Drug intolerance secondary to toxicities and nonadherence are significant factors in treatment failure.Entities:
Keywords: Internet; medication adherence; mobile phone; neoplasms
Year: 2017 PMID: 29212628 PMCID: PMC5738545 DOI: 10.2196/mhealth.8349
Source DB: PubMed Journal: JMIR Mhealth Uhealth ISSN: 2291-5222 Impact factor: 4.773
Figure 1Flowchart of the nurse-mediated telehealth (including REMIND system) intervention package (CML, chronic myeloid leukaemia; HP, health professional; QPL, question prompt list; RA, research assistant; SMS, short message service).
Figure 2REMIND system representation. (A) Architecture of the REMIND system showing context of interaction with different types of users (patients, health care professionals, and administrators) and external SMS Gateway service. The patient receives reminders on his or her cellular phone, sent from the SMS Gateway, and can interact with the weekly symptoms survey via a browser on a standard computer or a smartphone. (B) Screenshot of patient dashboard, showing graphs (from left to right) of scores (for severity and irritation) for symptom (in this case, nausea) over time, bar chart indicating daily adherence (measured by response), and pie chart showing overall adherence rate. (C) Screenshot of specific symptoms—severity graph for nausea—as displayed on the cellular smartphone interface.
Figure 3CONSORT flowchart of participants completing each intervention component and data collection point (RA refers to research assistant).
Participant demographics.
| Characteristics | Patients (N=9) | |
| Median (interquartile range) | 54 (44.5-60.0) | |
| Range | 35-72 | |
| Male | 6 (67) | |
| Female | 3 (33) | |
| Australia | 7 (78) | |
| China | 1 (11) | |
| England | 1 (11) | |
| Yes | 8 (89) | |
| No | 1 (11) | |
| Secondary/high school | 3 (33) | |
| Trade/Technical and Further Education | 1 (11) | |
| Bachelor’s degree | 3 (33) | |
| Postgrad diploma/masters/PhD | 2 (22) | |
| Median (interquartile range in years) | 4 (1-13) | |
| Range | 1 month-17 years | |
| Median (interquartile range in months) | 48 (16-123) | |
| Range | 15 days-12 years | |
| Full time | 4 (44) | |
| Part time | 2 (22) | |
| Home duties | 1 (11) | |
| Retired | 2 (22) | |
| Metropolitan | 4 (44) | |
| Rural | 5 (56) | |
aDuration on imatinib at the start of REMIND study: Patient 2 (9 years), Patient 3 (5 years), Patient 4 (4 years), Patient 5 (2.5 years), Patient 6 (11.5 years), Patient 7 (1 year), Patient 8 (1.6 years), Patient 9 (12 years), Patient 10 (2 weeks).
System administrator details of SMS (short message service) texts sent and answered by patients.
| Patient | Total days | SMS failure, n (%) | Patient failure to answer SMS when sent, n (%) | |
| In 2 hours of SMS | Not at all | |||
| 2 | 74 | 5 (7) | 5 (7) | 5 (7) |
| 3 | 79 | 1 (1) | 3 (4) | 3 (4) |
| 4 | 62 | 0 (0) | 4 (7) | 3 (5) |
| 5 | 69 | 0 (0) | 14 (20) | 10 (15) |
| 6 | 120 | 0 (0) | 8 (7) | 6 (5) |
| 7 | 79 | 0 (0) | 4 (5) | 4 (5) |
| 8 | 80 | 1 (1) | 32 (41) | 17 (22) |
| 9 | 57 | 0 (0) | 2 (4) | 0 (0) |
| 10 | 75 | 4 (5) | 8 (11) | 8 (11) |